ライフサイエンスコーパス: TDF

1 TDF 150 mg every 24 hours provides comparable systemic e

2 TDF alone is safe and effective for treatment of patient

3 TDF completely suppressed HBV DNA in 131 patients (92 %)

4 TDF PrEP prevented vaginal HIV acquisition in a dose-dep

5 TDF use did not attenuate renal function recovery or inc

6 TDF was associated with a lower hip T score (P = .02).

7 TDF-treated patients with chronic hepatitis B have reduc

8 In arm 1, TDF/FTC was added for 12 weeks, followed by 12 weeks of

9 measured the DNA methylation profiles of 10 TDFs from OAC with 12 NDF from normal oesophageal mucosa

10 altegravir [RAL], 74.7%; 95% CI, 41.4%-100%; TDF+FTC+ boosted darunavir [DRV/r], 93.9%; 95% CI, 90.2%

11 A total of 259 subjects (130 MVC, 129 TDF) contributed to the analyses (91% male; median age,

12 760 [41.7%]; ARR, 1.15; 95% CI, 1.04-1.27); TDF-FTC and lopinavir-ritonavir (TDF-FTC-LPV-R) (112 of

13 pulation (TDF HR = 0.18, 95% CI: 0.06, 0.53; TDF/FTC HR = 0.15, 95% CI: 0.04, 0.52); and 3) in per-pr

14 analysis (TDF HR = 0.18, 95% CI: 0.06, 0.53; TDF/FTC HR = 0.16, 95% CI: 0.05, 0.53).

15 9, 95% confidence interval (CI): 0.07, 0.56; TDF/FTC HR = 0.12, 95% CI: 0.03, 0.52); 2) with IPC weig

16 tonavir [LPV/r], 71.1%; 95% CI, 43.6%-98.6%; TDF+FTC+raltegravir [RAL], 74.7%; 95% CI, 41.4%-100%; TD

17 n 5 (MVC), 13 (MVC-FTC), 9 (MVC-TDF), and 8 (TDF-FTC) participants; rates did not differ among regime

18 ency virus RNA suppression while receiving a TDF- or tenofovir alafenamide-containing regimen.

19 al [CI], 66.1%-90.7%) for people receiving a TDF-based regimen and 58.8% (95% CI, 47.2%-70.4%) for a

20 pate in a behavioral intervention and accept TDF/FTC as PrEP.

21 s and TDF did not result in major additional TDF-related renal toxicity in HIV-infected patients.

22 stimated 100% probability of high adherence (TDF hazard ratio (HR) = 0.19, 95% confidence interval (C

23 ar mass black holes, which suggests that all TDFs could be accompanied by a jet.

24 .04, 0.52); and 3) in per-protocol analysis (TDF HR = 0.18, 95% CI: 0.06, 0.53; TDF/FTC HR = 0.16, 95

25 In the per-protocol analysis, TDF reduced shedding (relative risk [RR] = 0.74, P = .00

26 female sex (odds ratio = 7.05; P = .002) and TDF+emtricitabine treatment (odds ratio = 3.9; P = .01)

27 of emtricitabine (FTC, 200 mg; n = 139) and TDF (300 mg, FTC/TDF).

28 ing age, smoking, lower body mass index, and TDF exposure were independent predictors of low bone min

29 nt incidental exposure to MRP inhibitors and TDF did not result in major additional TDF-related renal

30 ns associated with FTC (K65R and M184IV) and TDF (K65R and K70E), using 454 sequencing.

31 nge {IQR}, 0.08-0.30]; n = 372), LDV/SOF and TDF/PI (0.17 [IQR, 0.04-0.30]; n = 100), and LDV/SOF wit

32 lus tenofovir disoproxil fumarate (TDF), and TDF plus FTC.

33 MVC-tenofovir disoproxil fumarate (TDF), and TDF-FTC (control).

34 patitis B, TAF appears to be as effective as TDF, with lower bone and renal toxicity.

35 lts of participants enrolled in the Botswana TDF/FTC Oral HIV Prophylaxis Trial, the Bangkok Tenofovi

36 bo for 12 weeks (placebo period) followed by TDF/FTC for 12 weeks and placebo for 12 additional weeks

37 Coformulated TDF/FTC has an intrinsic lipid-lowering effect, likely a

38 evidence supporting the use of coformulated TDF and 3TC/FTC as preferred backbone drugs for PEP.

39 to receipt of tenofovir (TDF), coformulated TDF/emtricitabine (FTC), or placebo.

40 mong infants exposed to ART from conception, TDF-FTC-EFV was associated with a lower risk for adverse

41 ths in patients with >/=1 year of continuous TDF exposure.

42 In a study of daily TDF/emtricitabine (FTC) preexposure prophylaxis (PrEP) i

43 reexposure prophylaxis]) of 30 days of daily TDF/FTC followed by 30 days off drug were evaluated.

44 al intervention and were provided with daily TDF/FTC as PrEP for 48 weeks.

45 2 +/- 0.39 log10 IU/mL) or TDF 300 mg daily (TDF group, n = 62, HBV DNA 8.18 +/- 0.47 log10 IU/mL) fr

46 sessed factors associated with discontinuing TDF in those with an exposure duration of >6 months.

47 We observed declines in the eGFR during TDF exposure (mean slopes, -15.7 mL/minute/1.73 m(2)/yea

48 tudy shows that a decline in the eGFR during TDF therapy was not fully reversible in one third of pat

49 IV-infected, HSV-2-uninfected persons during TDF-containing ART.

50 oxil fumarate, emtricitabine, and efavirenz (TDF-FTC-EFV) (901 of 2472 [36.4%]) compared with TDF-FTC

51 PI or NNRTI and a backbone containing either TDF/FTC or ABC/3TC.

52 fovir disoproxil fumarate and emtricitabine (TDF-FTC) for preexposure prophylaxis (PrEP) is an effect

53 tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ri

54 tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) doses required to achieve and maintain (after d

55 tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for PrEP is only licensed for adults.

56 tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ri

57 umarate (TDF), oral tenofovir-emtricitabine (TDF-FTC), or 1% tenofovir (TFV) vaginal gel as preexposu

58 were randomized to tenofovir-emtricitabine (TDF/FTC) plus atazanavir-ritonavir (ATV/r), darunavir-ri

59 vudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC) in 1857 human immunodeficiency virus type 1-inf

60 with a backbone of tenofovir/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/3TC).

61 loped in patients older than 50 years at ETV/TDF onset.

62 The HCC risk decreases beyond year 5 of ETV/TDF therapy in Caucasian chronic hepatitis B patients, p

63 nts without HCC at baseline who received ETV/TDF for >/=1 year.

64 ce beyond year 5 of entecavir/tenofovir (ETV/TDF) therapy and tried to determine possible factors ass

65 ats exhibit a trophic discrimination factor (TDF) similar to other terrestrial organisms and that del

66 Total dietary fiber (TDF) content of noodles made from rice flour was 3.0% an

67 including the levels of total dietary fibre (TDF), protein, inulin, total carbohydrates and lipids we

68 Tumour derived fibroblasts (TDFs) differ functionally from normal fibroblasts (NDFs)

69 own thermal stellar tidal disruption flares (TDFs) have not yet produced a conclusive detection.

70 Following TDF discontinuation, 38.6% of patients with a decline in

71 ine in hip BMD (n = 115 for MVC, n = 109 for TDF) at week 48 was less with MVC (median [Q1, Q3] of -1

72 .93%, -0.11%] vs -2.40% [-4.30%, -1.32%] for TDF (P < .001).

73 analyses found efficacy estimates of 67% for TDF and 75% for TDF/FTC.

74 fficacy estimates of 67% for TDF and 75% for TDF/FTC.

75 ue to adverse drug reactions were lowest for TDF+FTC+RAL (1.9%; 95% CI, 0%-3.8%) and highest for ZDV+

76 iving PrEP with TDF alone or combination FTC+TDF compared with placebo at conception.

77 icitabine/tenofovir disoproxil fumarate (FTC+TDF), is efficacious for prevention of human immunodefic

78 ne or in combination with emtricitabine (FTC-TDF) reduces the risk for HIV-1 acquisition.

79 ), alone or combined with emtricitabine (FTC-TDF), compared with placebo.

80 he frequency of tubulopathy was 1.7% for FTC-TDF versus 1.3% for placebo (odds ratio, 1.30; 95% confi

81 Daily oral FTC-TDF PrEP was not significantly associated with tubulopat

82 Of 1549 persons studied (776 receiving FTC-TDF, 773 receiving placebo), 64% were male, and the medi

83 In 498 participants (247 FTC/TDF, 251 placebo), BMD in those randomized to FTC/TDF de

84 , which did not differ between the arms (FTC/TDF vs placebo, P = .81).

85 EVG/c/FTC/TDF led to greater decreases in sCD14, hsCRP, and Lp-PLA

86 Significant differences favoring EVG/c/FTC/TDF were noted for changes in sCD14, hsCRP, and Lp-PLA2

87 ine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) with that of efavirenz/emtricitabine/tenofovir diso

88 luded random assignment to receive EVG/c/FTC/TDF, higher baseline sCD14 level, and larger decreases i

89 abine/tenofovir disoproxil fumarate (EFV/FTC/TDF).

90 P, and Lp-PLA2 levels, compared with EFV/FTC/TDF.

91 arms (7.8 cases per 100 person-years for FTC/TDF vs 6.8 cases per 100 person-years for placebo, P = .

92 abine and tenofovir disoproxil fumarate (FTC/TDF) decreases the risk of human immunodeficiency virus

93 bine plus tenofovir disoproxil fumarate (FTC/TDF) or TDF alone reduces the risk of human immunodefici

94 l emtricitabine/TFV disoproxil fumarate (FTC/TDF).

95 d emtricitabine 200 mg/tenofovir 300 mg (FTC/TDF) once daily.

96 (FTC, 200 mg; n = 139) and TDF (300 mg, FTC/TDF).

97 We report the effect of FTC/TDF on BMD in HIV-seronegative men who have sex with men

98 ouble-blind, placebo-controlled trial of FTC/TDF PrEP.

99 Within the largest randomized trial of FTC/TDF versus TDF as PrEP, plasma samples were tested for H

100 to rebound following discontinuation of FTC/TDF.

101 seline (23/52 [44%] on TDF, 4/7 [57%] on FTC/TDF).

102 r up to 16 weeks and received placebo or FTC/TDF pericoitally.

103 Oral FTC/TDF maintains efficacy in a macaque model of sexually tr

104 for the intermittent gel and daily oral FTC/TDF regimens, but lower for the daily gel regimen.

105 y in the event of no RAI), or daily oral FTC/TDF.

106 In HIV-uninfected persons, FTC/TDF PrEP was associated with small but statistically sig

107 Of 121 HIV seroconverters, 25 received FTC/TDF, 38 received TDF, and 58 received placebo.

108 tions randomized to FTC/TDF, none showed FTC/TDF mutations by clinical assays despite detectable drug

109 ug resistance was rare in iPrEx on-study FTC/TDF-randomized seroconverters, and only as low-frequency

110 ial and whether emtricitabine/tenofovir (FTC/TDF) modified that association.

111 ion, resistance was more frequent in the FTC/TDF arm (4 of 7 [57%]), compared with the TDF arm (1 of

112 tients in the TDF group and 86.3% in the FTC/TDF group had levels of HBV DNA <69 IU/mL (P = .43).

113 een groups; only 1 patient (0.7%) in the FTC/TDF group lost hepatitis B surface antigen.

114 y gel use for HIV protection compared to FTC/TDF (OR, 0.38; P < .001).

115 251 placebo), BMD in those randomized to FTC/TDF decreased modestly but statistically significantly b

116 Two randomized to FTC/TDF had minor variant M184I detected at 0.53% by AS-PCR

117 the 48 on-study infections randomized to FTC/TDF, none showed FTC/TDF mutations by clinical assays de

118 e measured in participants randomized to FTC/TDF.

119 s detected in 53% of those randomized to FTC/TDF.

120 RAI gel (IRR, 0.90; P = .51) compared to FTC/TDF.

121 5% maintained levels <400 copies/mL with FTC/TDF intensification as needed.

122 V/r monotherapy after first-line VF with FTC/TDF intensification when needed provides durable suppres

123 Minor variants with FTC/TDF mutations K65R, K70E, M184V/I were measured using 45

124 had ever used tenofovir disoproxil fumarate (TDF) (1.40; 1.15-1.70) or who were currently on TDF (1.2

125 ntiretroviral tenofovir disoproxil fumarate (TDF) alone or in combination with emtricitabine (FTC-TDF

126 (PrEP), using tenofovir disoproxil fumarate (TDF) and combination emtricitabine/tenofovir disoproxil

127 ombination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) or placebo before and after

128 ne (RPV), and tenofovir disoproxil fumarate (TDF) as a 3-drug, single-tablet regimen for PEP in men w

129 some form of tenofovir disoproxil fumarate (TDF) as part of their HIV treatment regimen.

130 The approved tenofovir disoproxil fumarate (TDF) dose of 300 mg every 48 hours for adults with moder

131 Tenofovir disoproxil fumarate (TDF) has been linked to renal impairment, but the extent

132 spread use of tenofovir disoproxil fumarate (TDF) in pregnant and breastfeeding women, few data exist

133 y of maternal tenofovir disoproxil fumarate (TDF) in reducing mother-to-infant hepatitis B virus (HBV

134 Tenofovir disoproxil fumarate (TDF) is active against lamivudine-resistant hepatitis B

135 Tenofovir disoproxil fumarate (TDF) is an established nucleotide analogue in the treatm

136 Tenofovir disoproxil fumarate (TDF) is associated with proximal tubular dysfunction (tu

137 Tenofovir disoproxil fumarate (TDF) is commonly used in antiretroviral treatment (ART)

138 Exposure to tenofovir disoproxil fumarate (TDF) may cause renal toxicity.

139 Tenofovir disoproxil fumarate (TDF) plays a pivotal role in antiretroviral therapy (ART

140 s of systemic tenofovir disoproxil fumarate (TDF) PrEP revealed reduced efficacy in women compared to

141 w response to tenofovir disoproxil fumarate (TDF) treatment, have been examined to identify structura

142 Although tenofovir disoproxil fumarate (TDF) use has increased as part of first-line antiretrovi

143 g LDV/SOF and tenofovir disoproxil fumarate (TDF) without a protease inhibitor (PI) (0.18 [interquart

144 ce-daily oral tenofovir disoproxil fumarate (TDF), alone or combined with emtricitabine (FTC-TDF), co

145 TC), MVC plus tenofovir disoproxil fumarate (TDF), and TDF plus FTC.

146 ne (FTC), MVC-tenofovir disoproxil fumarate (TDF), and TDF-FTC (control).

147 e high use of tenofovir disoproxil fumarate (TDF), emtricitabine, and lamivudine and potential transm

148 successor of tenofovir disoproxil fumarate (TDF), has been approved in the United States and Europe

149 ent with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtricitabine (TDF-FTC), or 1% teno

150 el containing tenofovir disoproxil fumarate (TDF), the more potent prodrug of tenofovir (TFV), but no

151 el containing tenofovir disoproxil fumarate (TDF), the tenofovir prodrug, but not with the tenofovir

152 is unknown if tenofovir disoproxil fumarate (TDF), which is often coformulated with the lipid-neutral

153 roc (MVC)- to tenofovir disoproxil fumarate (TDF)-containing ART.

154 ne changes in tenofovir disoproxil fumarate (TDF)-related bone toxicity.

155 formulation, tenofovir disoproxil fumarate (TDF).

156 itabine (FTC)/tenofovir disoproxil fumarate (TDF).

157 ction to oral tenofovir disoproxil fumarate (TDF)/placebo vaginal gel, oral placebo/tenofovir (TFV) v

158 n either oral tenofovir disoproxil fumarate (TDF, 300 mg) and placebo (n = 64) or a combination of TD

159 Tenofovir disoproxyl fumarate (TDF) disoproxyl fumarate (TDF) has in vitro activity aga

160 soproxyl fumarate (TDF) disoproxyl fumarate (TDF) has in vitro activity against herpes simplex virus

161 y merit a downward adjustment, using generic TDF-based costs as the benchmark.

162 were randomly assigned (1:1) to groups given TDF (300 mg, n = 141) or a combination of emtricitabine

163 to determine bone mineral density changes in TDF-exposed patients.

164 e mineral density loss has been described in TDF-treated patients with human immunodeficiency virus i

165 f which 3,243 (66.8%) were hypomethylated in TDFs compared to NDFs.

166 When administered at 50 mg/kg, TDF achieved plasma TFV concentrations (370 ng/ml) that

167 intervention in conjunction with open-label TDF/FTC.

168 Maternal TDF use did not adversely affect perinatal outcomes.

169 acquired HIV infection (4 MVC alone, 1 MVC + TDF; overall annualized incidence, 1.4% [95% confidence

170 ts occurred in 5 (MVC), 13 (MVC-FTC), 9 (MVC-TDF), and 8 (TDF-FTC) participants; rates did not differ

171 One death (by suicide) occurred in the MVC-TDF group but was judged not to be related to study drug

172 Neither TDF nor TFV gel decreased overall shedding or lesion rat

173 Using a new TDF formulation, we compared the pharmacokinetics of the

174 No TDF resistance developed through 96 weeks of treatment.

175 In patients without viral suppression, no TDF-related resistance mutations were found.

176 aseline was lower in the TDF than in the non-TDF group (1.9% vs 4.0%).

177 e safety, tolerability, and acceptability of TDF/FTC and patterns of use, rates of adherence, and pat

178 00 over the average wholesale price (AWP) of TDF.

179 A backbone of TDF/FTC was received by 67% of PI users and 69% of NNRTI

180 mg) and placebo (n = 64) or a combination of TDF (300 mg) and emtricitabine (200 mg, n = 62) for 192

181 eGFR increases following discontinuation of TDF therapy (mean slopes, 12.5 mL/minute/1.73 m(2)/year

182 eline, a lower eGFR after discontinuation of TDF therapy, and more-prolonged exposure to TDF were ass

183 e recovery 6 months after discontinuation of TDF therapy.

184 The median duration of TDF exposure was 54 months, and the total cumulative exp

185 The efficacy of TDF to suppress HBV (HBV DNA <20 IU/mL) and the influenc

186 Inhibitors of TDF's apical multidrug-resistance-associated protein eff

187 Initiation of TDF decreases bone mineral density (BMD) in HIV-infected

188 4; 95% CI, 1.19 to 3.85) since initiation of TDF therapy.

189 gnificantly (P<0.05) increased the levels of TDF and inulin whilst decreasing carbohydrates, lipids a

190 undetectable HBV viral load at six months of TDF-containing ART.

191 Participants took a median of 15 pills of TDF-FTC or placebo per month (P=0.57).

192 dings support the short-term renal safety of TDF/FTC PrEP in HIV-seronegative young men and suggest t

193 reassuring and support the continued use of TDF in pregnancy.

194 The use of TDF-FTC before and after sexual activity provided protec

195 with 10-24 weeks, and 188 with <10 weeks of TDF exposure.

196 changes compared to baseline (23/52 [44%] on TDF, 4/7 [57%] on FTC/TDF).

197 ) (1.40; 1.15-1.70) or who were currently on TDF (1.25; 1.05-1.49) had higher incidence of fractures.

198 At 12 months, one TDF-group child newly developed HBsAg positivity, presum

199 R5 tropism were randomized to MVC 150 mg or TDF 300 mg once daily (1:1), stratified by VL <100 000 o

200 = 56, HBV DNA 8.22 +/- 0.39 log10 IU/mL) or TDF 300 mg daily (TDF group, n = 62, HBV DNA 8.18 +/- 0.

201 s tenofovir disoproxil fumarate (FTC/TDF) or TDF alone reduces the risk of human immunodeficiency vir

202 Oral TDF modestly decreased HSV shedding and lesion rate, and

203 ized, placebo-controlled trial of daily oral TDF, alone or with emtricitabine (FTC), in HIV-uninfecte

204 rticipants randomly assigned to receive oral TDF-FTC than among those assigned to receive oral placeb

205 iety ought to be willing to pay for TAF over TDF, in exchange for its improved toxicity profile.

206 he response to antiviral drugs, particularly TDF, is poorly understood.

207 the majority of which had detectable plasma TDF (8 of 9; 88.9%).

208 roximate a continuously adherent population (TDF HR = 0.18, 95% CI: 0.06, 0.53; TDF/FTC HR = 0.15, 95

209 ween adverse perinatal outcomes and prenatal TDF use.

210 C/NVP (34%); 49% of pregnancies had prenatal TDF exposure and 6% used a protease inhibitor.

211 sed to determine the association of prenatal TDF and perinatal outcomes.

212 rend in the proportion of persons prescribed TDF-FTC for PrEP during the study period, with 417 users

213 persons aged >/=16 years who were prescribed TDF-FTC for PrEP each year.

214 hird of patients and suggests that prolonged TDF exposure at a low eGFR should be avoided.

215 om participants randomly assigned to receive TDF, TDF-FTC, and TFV gel, respectively.

216 converters, 25 received FTC/TDF, 38 received TDF, and 58 received placebo.

217 ersons, 68 acquired HSV-2, with 24 receiving TDF-containing ART and 44 receiving ART without TDF (HSV

218 nine clearance 30 to <50 mL/minute receiving TDF 300 mg every 48 hours as part of a nonnucleoside rev

219 ica, renal outcomes among patients receiving TDF remain poorly understood.

220 >/=25 weeks were older than those receiving TDF for 10-24 or <10 weeks (median age, 31 vs 28 and 28

221 d a suppressed viral load and were receiving TDF as a part of combination antiretroviral therapy.

222 Women receiving TDF for >/=25 weeks were older than those receiving TDF

223 (1) provide additional safety data regarding TDF/FTC use among young MSM who had negative test result

224 tes were highest for the TDF-based regimens (TDF+emtricitabine [FTC]+lopinavir/ritonavir [LPV/r], 71.

225 1.04-1.27); TDF-FTC and lopinavir-ritonavir (TDF-FTC-LPV-R) (112 of 231 [48.5%]; ARR, 1.31; 95% CI, 1

226 ng 3-drug PEP received single-tablet FTC-RPV-TDF once daily for 28 days.

227 A single-tablet regimen of FTC-RPV-TDF was well tolerated as once-daily PEP, with high leve

228 odel to perform a PK-PD analysis of systemic TDF PrEP for vaginal HIV acquisition.

229 adverse event was lower among people taking TDF-based PEP (0.3%; 95% CI, 0%-1.1%) vs a ZDV-based reg

230 rticipants randomly assigned to receive TDF, TDF-FTC, and TFV gel, respectively.

231 Tenofovir (TDF) is considered the ideal treatment for patients coin

232 and the nucleotide RTI inhibitor tenofovir (TDF), show efficacy in blocking K103 RT.

233 es) were randomized to receipt of tenofovir (TDF), coformulated TDF/emtricitabine (FTC), or placebo.

234 ug regimens (zidovudine [ZDV]- or tenofovir [TDF]-based regimens), and 10 studies (1755 initiations)

235 bolite to target cells more efficiently than TDF at lower doses, thereby reducing systemic exposure t

236 eater frequency of resistance mutations than TDF.

237 r metabolite (TFV diphosphate) revealed that TDF PrEP efficacy was best described by plasma TFV level

238 The TDF analogue tenofovir alafenamide (TAF) has demonstrate

239 The TDF group had less incidence of maternal alanine aminotr

240 At delivery, the TDF group had lower maternal HBV DNA levels (4.29 +/- 0.

241 n, PEP completion rates were highest for the TDF-based regimens (TDF+emtricitabine [FTC]+lopinavir/ri

242 ek 96 of treatment, 89.4% of patients in the TDF group and 86.3% in the FTC/TDF group had levels of H

243 nal dysfunction at baseline was lower in the TDF than in the non-TDF group (1.9% vs 4.0%).

244 group and 76% of patients (47 of 62) in the TDF+emtricitabine group had levels of HBV DNA <69 IU/mL

245 week 192, 55% of patients (35 of 64) in the TDF+placebo group and 76% of patients (47 of 62) in the

246 sion occurred in 3 patients (5%), all in the TDF+placebo group; no patient had loss of hepatitis B su

247 fections occurred during follow-up, 2 in the TDF-FTC group (incidence, 0.91 per 100 person-years) and

248 have HIV infection were enrolled (199 in the TDF-FTC group and 201 in the placebo group).

249 0 person-years), a relative reduction in the TDF-FTC group of 86% (95% confidence interval, 40 to 98;

250 In the TDF-FTC group, as compared with the placebo group, there

251 Of the 121/123 newborns, the TDF group had lower rates of HBV DNA positivity at birth

252 ion may contribute to the maintenance of the TDF phenotype.

253 In the rest frame of the TDF, our radio observations are an order of magnitude mo

254 Multivariate analysis revealed that the TDF group had lower risk (odds ratio = 0.10, P = 0.0434)

255 was performed at enrollment, after which the TDF dose was changed to 150 mg once daily.

256 TC/TDF arm (4 of 7 [57%]), compared with the TDF arm (1 of 19 [5.3%]; P = .01), owing to the FTC-asso

257 on of variable radio emission from a thermal TDF, which we interpret as originating from a newly laun

258 shown that TAF may be a good alternative to TDF for treating chronic hepatitis B.

259 ipid-lowering effect, likely attributable to TDF.

260 tion (PTH-FGF23) is a primary contributor to TDF-associated BMD decline in this age group.

261 less frequently among pregnancies exposed to TDF (aPRR, 0.34, P = .02).

262 0 patients were studied: 122 were exposed to TDF, and 48 were controls.

263 o association between cumulative exposure to TDF and fractures (1.08/5 y exposure; 0.94-1.25).

264 een pregnancies with and without exposure to TDF in the frequency of pregnancy loss (adjusted prevale

265 TDF therapy, and more-prolonged exposure to TDF were associated with an increased risk of incomplete

266 Exposure to TDF, but not other ARVs, was an independent risk factor

267 Exposure to TDF/FTC reduced TC from 234 to 205 mg/dL (P < .001), LDL

268 No HBV resistance mutations to TDF were found in patients with delayed response, but al

269 articipants with detectable HBV DNA prior to TDF therapy were selected from the Swiss HIV Cohort Stud

270 d in patients with slow or rapid response to TDF treatment.

271 ivudine treatment in the delayed response to TDF warrant further investigation.

272 ons/T215rev, showed no impact on response to TDF- or tenofovir alafenamide-containing regimens.

273 ssociated with the differential responses to TDF treatment.

274 of 111 HIV-HBV-infected patients undergoing TDF-containing antiretroviral therapy were prospectively

275 ssociations between the duration of in utero TDF exposure and change in FLZ and HLZ.

276 no association between duration of in utero TDF exposure per 1-week increment and change in FLZ (ss

277 The duration of in utero TDF exposure was calculated in weeks.

278 ist on fetal bone development after in utero TDF exposure.

279 e largest randomized trial of FTC/TDF versus TDF as PrEP, plasma samples were tested for HIV with res

280 After 12 weeks, TDF/FTC exposure was associated with lower TC and LDL-c

281 The most frequent ART regimens were TDF/3TC/EFV (39%) and AZT/3TC/NVP (34%); 49% of pregnanc

282 Whether TDF-containing antiretroviral therapy (ART) reduces HSV-

283 We evaluated whether TDF causes tubulopathy when used as HIV preexposure prop

284 With TDF/FTC use, no clear association was found among PI use

285 analysis, the effectiveness was -49.0% with TDF (hazard ratio for infection, 1.49; 95% confidence in

286 nce interval [CI], 0.97 to 2.29), -4.4% with TDF-FTC (hazard ratio, 1.04; 95% CI, 0.73 to 1.49), and

287 tment-naive participants initiating ART with TDF/FTC, no differences in lean mass and regional fat we

288 ymorphic sites and none were associated with TDF resistance.

289 and triglyceride levels did not change with TDF/FTC exposure.

290 s were safe and well tolerated compared with TDF + FTC; this study was not powered for efficacy.

291 FTC-EFV) (901 of 2472 [36.4%]) compared with TDF-FTC and nevirapine (NVP) (317 of 760 [41.7%]; ARR, 1

292 s were safe and well-tolerated compared with TDF-FTC in U.S. women.

293 Compared with TDF-FTC-EFV, all other regimens were associated with hig

294 ss at the hip and lumbar spine compared with TDF.

295 and bone mineral density loss compared with TDF.

296 gher (32%) safety risk compared to men; with TDF/FTC, the safety risk was 20% larger for women compar

297 ally different for women receiving PrEP with TDF alone or combination FTC+TDF compared with placebo a

298 tion did not worsen on LDV/SOF regimens with TDF.

299 Treatment with TDF for highly viremic mothers decreased infant HBV DNA

300 -containing ART and 44 receiving ART without TDF (HSV-2 seroconversion incidence, 6.42 and 6.63 cases

301 R, 0.04-0.30]; n = 100), and LDV/SOF without TDF (0.15 [IQR, 0.00-0.30]; n = 423).